Newron Pharmaceuticals

FDA headquarters
#Clinical trial #FDA #Newron Pharmaceuticals #Schizophrenia

FDA pauses schizophrenia trial after patient death 

The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant.  Evenamide, developed by biopharmaceutical company Newron Pharmaceuticals, was being evaluated in the Phase III ENIGMA-TRS 2 study, targeting the modulation of excessive release of glutamate in… Read More

#News #Regulatory

Node structures in the central nervous system
#Clinical trial #Newron Pharmaceuticals #Schizophrenia

Newron raises €38m to advance schizophrenia treatment 

Biopharmaceuticals company Newron Pharmaceuticals has secured €38 million to advance novel therapies for patients with diseases of the central and peripheral nervous system.  The capital, raised through newly issued shares, is set to accelerate the company’s ENIGMA-TRS Phase III programme, evaluating the safety and efficacy of evenamide as an add-on therapy… Read More

#News

Brain physiology
#Neuroscience #Newron Pharmaceuticals #Schizophrenia

Drug’s unique mechanism of action targets schizophrenia abnormalities

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic… Read More

#Editor's Choice #News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia

Study in schizophrenia patients shows positive top-line results 

Newron Pharmaceuticals has announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.   The… Read More

#News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia #Treatment resistance

“Highly encouraging” results for schizophrenia drug

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of… Read More

#News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News